Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel + cisplatin + S-1 for stage IB-IIIA esophageal squamous cell carcinoma
ChiCTR1800014659Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and tegafur in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henan Cancer Hospital. Primary endpoint: Overall response rate. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
docetaxelcisplatintegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1800014659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014659.